Who
Derrell Porter
Director
Company insider
Files Form 4 as: Director, Acumen Pharmaceuticals; Director, Passage Bio; SVP, Head of Global Commercial, Atara Biotherapeutics.
In numbers
- Trades disclosed
- 44
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $1.2M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 10 May 2017
- Last trade
- 17 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 17 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,040 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $14K13,040 at $1.07 | filing |
| 17 Jun 2026filed 17 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $30K13,040 at $2.33 | filing |
| 17 Jun 2026filed 17 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,040 at $0.00 | filing |
| 17 Jun 2026filed 17 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $14K13,040 at $1.07 | filing |
| 17 Jun 2026filed 17 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $30K13,040 at $2.33 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $30K12,800 at $2.33 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $30K12,800 at $2.33 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $6,9126,460 at $1.07 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $15K6,460 at $2.35 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,460 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,460 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $6,9126,460 at $1.07 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $15K6,460 at $2.35 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —35,500 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —35,500 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,539 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PASG Passage Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,539 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.